PRISMS Trial Conclusions Rebif efficacy is sustained over 4 years as measured by: –MRI –Relapses –Disability 44 mcg TIW yields greater efficacy than 22 mcg TIW Patients treated at a high dose early have better outcomes With respect to NAbs, treatment decisions are best made on clinical grounds –By year 4: 7/8 patients are NAb-free Side effects are generally mild and manageable PRISMS Study Group.
{}